Major Histocompatibility Complex 2016; 23 (3): 168 184 1) 2) 3) 4) 5) 1) 6) 7) 8) 1) 2) 3) 4) HLA 5) 6) 7) 8) HLA 11 25 28 10 22 1 4 61 44 6 1 10 11 5 HLA 60 3 27 3 5 9 5 10 19 5 50 22.4 5.9 8.2% 78.7% 44.8% 19.1% 8 21.3% 78.7% 57.6% 19.7% 27 49 24.4 5.0 4.7% 85.9% 49.8% 20.7% 28 28 40% 168
MHC 2016; 23 (3) 40% 20 5 20% 5 40% 1 MHC II a e a b c d e a 11.5%, b, c MHC II 2 MHC I a e a 65.6%, e 169
MHC 2016; 23 (3) 3 1980 3 a e 1 G.D. Snell 2 J. Dausset 3 B. Benacerraf 4 J.J. van Rood 5 B. Amos a 1, 2, 3 b 2, 3, 4 c 1, 2, 4 d 2, 4, 5 e 3, 4, 5 a 19.7% c, b 26 3 1980 MHC GD Snell J Dausset B. Benaceraf 3 G.D. Snell H-2 J. Dauseet HLA B. Benacerraf Ir J.J. van Rood HLA B. Amos HLA 4 HLA-A2 a e a HLA-A*02:01 b HLA-A*02:02 c HLA-A*02:03 d HLA-A*02:04 e HLA-A*02:06 a 45.9%, c 5 a e a 2 b 1 c 1 d e DNA 170
MHC 2016; 23 (3) 50.8% c 6 a e a DNA b 4 c d e 2 c 24.6%, b DNA 2 2 1 1 7 MHC a e a H-2 b RT c BoLA d Mamu e Cpz 21.3%, c, b MHC ChLA 8 HLA a e a WHO b WHO c WHO d WHO e 6 52.5% 9 HLA a e a HLA I HLA-C b HLA II c HLA I 1 171
MHC 2016; 23 (3) d HLA II 3 e HLA II 63.9% 10 HLA a e a I II b I II c B I II d I e 2 II c 67.2% 11 HLA I a e a 2 b c 9 11 d e CD8 a 62.3% 12 HLA a e a HLA-E b HLA-C c MIC-C d TNF-A e PSMB9 c 45.9%, e 13 MIC a e a MIC-A MIC-B b MIC HLA II c MIC d MIC-B 2 172
MHC 2016; 23 (3) e MIC-A, MIC-B NK c 36.1%, b MIC-A MIC-B MIC HLA I 2 MIC-A MIC-B NK NKG2D 14 II a e a GABBR1 b PSMB9 c C2 d TNF e TAPBP TAP 16.4%, e GABBR1 I C2 TNF III TAPBP II II PSMB9 PSMB9 TAP1 PSMB8 TAP2 15 HLA I a e 1 T 2 HLA I 3 HLA I T 4 HLA I T T 5 HLA I a 1, 2 b 1, 3 c 2, 3 d 3, 4 e 4, 5 42.6% c, e 16 HLA-DRB a e a DR1, DR8, DR10 DR51 b DR2 (DR15, DR16) DRB 2 c DR3, DR5, DR6 DR52 d DR4, DR7, DR9 DRB 1 e DR 1 42.6%, b 173
MHC 2016; 23 (3) 17 HLA II class II-associated invariant chain peptide CLIP ndosome/ lysosome CLIP CLIP a e a HLA-E b HLA-DM c HLA-DP d LMP e TAP 29.5%, d HLA-DM endosome/lysosome II CLIP II HLA-E HLA HLA I NK NKG2A/CD94 HLA-DP II LMP PSMB8 PSMB9 TAP TAP1 TAP2 18 HLA a e a HLA-A HLA-B T HLA-C T b TAP HLA II MIIC II c HLA-DO HLA-DM d MICA/MICB T e HLA-C NK NKG2A 23.0%, b HLA-C HLA-A HLA-B TAP HLA-DO HLA-DM ndosome/lysosome HLA II HLA-DO HLA-DM HLA-C NK KIR 19 NK a e a b c d e ADCC c 174
MHC 2016; 23 (3) 77.0% 20 a e a T b c d T e T a 39.3% T T T a 21 T T a e 1 T MHC 2 T MHC 3 T MHC 4 1 T T 5 T T a 1, 2 b 1, 5 c 2, 3 d 3, 4 e 4, 5 a 59.0% c 22 MHC T T a e a b c T d T e T 29.5% c, e somatic recombination B T T T MHC B T T T 175
MHC 2016; 23 (3) 23 MHC a e 1 MHC T 2 3 MHC T 4 NK MHC I 5 MHC a 1, 5 b 2, 4 c 1, 3 d 2, 3 e 3, 5 c 49.2% 24 MHC I a e a b c T d B e NK 63.9% a, b 25 a e 1 2 3 4 5 a 1, 2, 3 b 1, 2, 4 c 3, 4, 5 d 1, 3, 5 e 1, 3, 4 32.8%, b 26 a e a b c 20% 176
MHC 2016; 23 (3) d 1 e 78.7% c 27 30 a e a b c d e 47.5% a 28 a b c d e 27.9% c 29 a e 1 HLA HLA-A, B, C, DRB1 3 2 HLA-C GVHD 3 HLA-DPB1 4 HLA-A, B, C, DRB1 5 GVHD. a 1, 2 b 1, 4 c 2, 4 d 3, 4 e 4, 5 177
MHC 2016; 23 (3) 27.9%, c A, B, DR 3 6 1 2 2 HLA HLA-C GVHD T GVLD HLA GVHD HLA 30 GVHD a e a B HLA b 15 50 Gray c 1 2 I II d HLA e HLA 67.2% 31 a e 1 PTR HPA HLA 2 HLA HLA 3 HLA ABO A B 4 HLA I HLA II 5 HLA HLA a. 1, 2, 3 b. 1, 2, 5 c. 1, 4, 5 d. 2, 3, 4 e. 3, 4, 5 63.9%, b 32 HLA a e a HLA-B*52 b HLA-DRB1*04:05 c HLA-DRB1*15:01 d HLA-DRB1*04:06 e B HLA-DRB1*09:01 42.6% a, c 178
MHC 2016; 23 (3) 33 HLA a e 1 HLA-B*27 2 DRB1*15:01 3 1 DRB1*03:01 4 B*51:01 5 DRB1*04:05 a 1, 2 b 1, 3 c 2, 3 d 3, 4 e 4, 5 27.9% a, e HLA-B*27 DRB1*15:01 DRB1*04:01 DRB1*01:01 4 34 HFE a e a b c d e 44.3% a 35 a e a b HLA c d Hardy-Weinberg e Rh 0 (D) 57.4%, c 36 a e a 1980 b 2014 24 1 c ES d HLA e 179
MHC 2016; 23 (3) 21.3% c 1978 ES HLA 37 HLA HLA a e a 8 4 b c d null e phase ambiguity c 8.2%, d, e HLA NGS NGS Sanger pth 100 depth NGS Sanger 38 a e 1 a b c d e 18.0% c, d 39 1 PCR a e 1 180
MHC 2016; 23 (3) 2 3 4 5 a 1, 2 b 1, 4 c 2, 4 d 3, 4 e 4, 5 78.7%, c 40 LCT HLA a e 1 HLA I 2 T HLA I 3 B HLA II 4 HLA I II 5 HLA II a 1, 2 b 2, 3 c 3, 4 d 4, 5 e 1, 5 63.9% a 41 a e 1 1.077 2 3 4 CD8 B 5 a 1, 2 b 2, 4 c 3, 4 d 3, 5 e 1, 5 73.8% 42 LCT a e a HLA I II HLA I b HLA II HLA I c IgM HLA d HLA A B e AHG-LCT LCT 29.5% HLA I II 181
MHC 2016; 23 (3) IgM LCT HLA A B AHG-LCT IgM LCT LCT HLA 43 a e 1 HLA HLA 2 3 4 5 a 1, 2, 3 b 1, 2, 4 c 1, 3, 4 d 2, 3, 4 e 3, 4, 5 57.4%, c 44 MLR a e a T b NK c CD4 T d MLR e HLA I 29.5% MLR MHC HLA II CD4 T T II 45 DNA a e a PCR-SSP b PCR-SSO DNA c PCR-RFLP d PCR-SSCP e PCR-SBT PCR c 72.1% a 46 a e a HLA-DR HLA-DRA b HLA-DR15 HLA-DRB1*15:01 c HLA-B*15:26N HLA B15N 182
MHC 2016; 23 (3) d HLA-DR52 HLA-DRB4 e HLA-DQ HLA-DQA1 42.6% 47 HLA a e a A*02:03 A203 b A210 c A24 A9 d B*39:01 B39 e B*40:02 B60 11.5%, b, c HLA-A*02:03 A*02:10 A203 A210 A23 A24 A9 B*39:01 B39 B*40:02 B61 b. 48 a e a SNP b Y c Insertion-deletion d Variable number of tandem report e 41.0% a 49 a e a T B b CD3 T c IgG1 d IgG4 e CD19 B 63.9%, b, c 50 a e 183
MHC 2016; 23 (3) a b c d e 39.3%, c 2 2 184